Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00789737 · ClinicalTrials.gov registry record · Phase 3
Welchol as Monotherapy for Type 2 Diabetes Mellitus
A Phase 3 study of Type 2 Diabetes Mellitus, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 357
- Enrollment target
- 20
- Study locations
NCT00789737: Completed Phase 3 study of Type 2 Diabetes Mellitus, sponsored by Daiichi Sankyo.
NCT00789737 is a Phase 3 study of Type 2 Diabetes Mellitus that has completed, run by Daiichi Sankyo. The registered enrollment target is 357 participants, below the 2,957-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00789737, a Phase 3 study of Type 2 Diabetes Mellitus, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 357 participants
- Enrollment target
- 20
- Study locations
Study Summary
The current study investigates Welchol as monotherapy to improve glycemic control in subjects with Type 2 Diabetes Mellitus not adequately controlled with diet and exercise alone. The study will evaluate if Welchol monotherapy for Type 2 Diabetes Mellitus will be safe, well tolerated and efficacious.
Primary Outcome
change in HbA1c from baseline to Week 24
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Welchol
Study Locations (20)
California
- - Buena Park
- - Burbank
- - Chula Vista
- - Garden Grove
- - Huntington Park
- - Irvine
- - La Mirada
- - Lincoln
- - Lomita
Arizona
- - Green Valley
- - Mesa
- - Mesa
- - Tucson
- - Tucson
- - Tucson
Alabama
- - Birmingham
- - Birmingham
- - Montgomery
- - Muscle Shoals
Arkansas
- - Searcy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 357 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
What the finished NCT00789737 record still lists
NCT00789737 is an interventional study that assigns participants to a tested intervention. The registered 357 participants enrollment target is mid-sized for trials with a published cap, below the 2,957-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00789737 names 20 study sites across 4 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00789737 about?
NCT00789737 is a clinical study titled "Welchol as Monotherapy for Type 2 Diabetes Mellitus". The current study investigates Welchol as monotherapy to improve glycemic control in subjects with Type 2 Diabetes Mellitus not adequately controlled with diet and exercise alone. The study will evaluate if Welchol monotherapy for Type 2 Diabetes Mellitus will be safe, well tolerated and efficacious...
What is the current status of trial NCT00789737?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 357 participants. The study started on 2009-01. Estimated completion is 2011-12.
What conditions does trial NCT00789737 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT00789737?
The interventions under investigation include: Placebo (DRUG), Welchol (DRUG).
Who is sponsoring clinical trial NCT00789737?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00789737 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00789737's enrollment target sits among peer trials
357 25th of 130 higher than 106 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
RECRUITING · Phase 3
-
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
COMPLETED · Phase 3
-
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
COMPLETED · Phase 3
-
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
COMPLETED · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062888 · 357 participants · Phase 2
FFP In Traumatic BRAin INjury (FIT-BRAIN) Trial
- NCT06109766 · 357 participants · NA
Delivering Evidence-Based Parenting Services to Families in Child Welfare Using Telehealth
- NCT06231342 · 357 participants · NA
Endotracheal Tube (ETT) 180: Stylet-loaded Endotracheal Tube Rotation Before Insertion
- NCT06533826 · 357 participants · Phase 2
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia